Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Hypotensive effect of atorvastatin is not related to changes in inflammation and oxidative stress.
We sought to determine if atorvastatin lowers blood pressure in patients with previously diagnosed and well-controlled essential arterial hypertension and if this effect could be related to anti-inflammatory and anti-oxidative effects . Among 92 patients with essential arterial hypertension , we studied 56 non-smoking and normolipemic : 39 were r and omized to receive 80 mg atorvastatin daily for 3 months ( statin-treated patients , ST ) , and the rest continued a previous hypotensive therapy ( statin-free patients , SF ) . Blood pressure was measured using a 24-h ambulatory blood pressure measurement device . Serum levels of high-sensitivity C-reactive protein ( hs-CRP ) , total antioxidant status ( TAS ) and plasma peroxides ( assessed by Oxystat ) were measured in both groups . The mean change in systolic BP ( SBP ) for atorvastatin was -5.7 mmHg ( 95 % confidence interval CI , -4.1 to -7.2 mmHg ) , and the mean change in diastolic BP ( DBP ) was -3.9 mmHg ( 95 % CI , -2.7 to -5.0 mmHg ) . No change in BP in SF patients was observed . In the ST group , hs-CRP and peroxides did not significantly decrease . In the SF group , concentrations of hs-CRP proceeded to decrease while peroxides increased . In the ST group , changes in hs-CRP correlated with changes in total cholesterol and low-density lipoprotein cholesterol ( r = 0.41 , p = 0.013 and r = 0.35 , p = 0.04 , respectively ) but did not correlate with changes in BP . The hypotensive statin effect was independent of the hypolipemic effect . During three months of observation , TAS concentrations in both groups remained stable . In this r and omized study , additionally administered atorvastatin to non-smoking and normolipemic patients with well-controlled essential arterial hypertension result ed in reduction of BP . This effect was not followed by significant changes in hs-CRP , TAS or Oxystat concentrations . The hypotensive effect of atorvastatin did not depend on anti-inflammatory , anti-oxidative or hypolipemic actions
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .